Author | Wendy Stock, MD


COUNTERPOINT: Standard vs Investigational Agents as Upfront Treatment for High-Risk AML

March 15, 2017

As we learn more about the biology of AML, it appears that 7+3 only rarely clears residual leukemic clones in patients with higher-risk disease. New therapies are needed that can target and eradicate resistant subclones early in the disease course.

Hematopoietic Cell Transplantation, Second Edition

September 01, 2000

Hematopoietic Cell Transplantation, edited by Drs. Thomas, Blume, and Forman, is an excellent updated second edition of their comprehensive textbook designed for both practitioners involved in transplantation and those interested in the science of stem-cell transplantation.